The Changing Landscape of Alopecia Areata: The Translational Landscape

Advances in Therapy

Volumn 34, Issue 7, 2017, Pages 1586-1593

  Wang, Etienne C E ^a   Christiano, Angela M ^a  

^a Department of Medicine   (United States)

Author keywords

Alopecia areata; Basic science; Genetics; Immunodulation; Translational research

Indexed keywords

AUTOANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EZETIMIBE PLUS SIMVASTATIN; HLA ANTIGEN; JANUS KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; IMMUNOSUPPRESSIVE AGENT;

ALOPECIA AREATA; BIOLOGICAL THERAPY; CHROMOSOME 6Q; CYTOTOXIC T LYMPHOCYTE; DISEASE REGISTRY; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; HAIR FOLLICLE; HAIR ROOT; HLA SYSTEM; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRECLINICAL STUDY; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; SKIN GRAFT; ADVERSE DRUG REACTION; ANIMAL; IMMUNOLOGY; TRANSLATIONAL RESEARCH;

ALOPECIA AREATA; ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85021251310     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-017-0540-9     Document Type: Review

References (50)

1. Safavi KH, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628–33.
2. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.
3. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S16–22.
4. Petukhova L, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–7.
5. Colombe BW, et al. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995;33(5 Pt 1):757–64.
6. Barahmani N, et al. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006;126(1):74–8.
7. Moftah NH, et al. ULBP3: a marker for alopecia areata incognita. Arch Dermatol Res. 2016;308(6):415–21.
8. Betz RC, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.
9. Petukhova L, Christiano AM. Functional interpretation of genome-wide association study evidence in alopecia areata. J Invest Dermatol. 2016;136(1):314–7.
10. Penders AJ. Alopecia areata and atopy. Dermatologica. 1968;136(5):395–9.
11. Kuwano Y, et al. Serum chemokine profiles in patients with alopecia areata. Br J Dermatol. 2007;157(3):466–73.
12. Sadeghi S, et al. Study of Th1/Th2 balance in peripheral blood mononuclear cells of patients with alopecia areata. Acta Microbiol Immunol Hung. 2015;62(3):275–85.
13. Suarez-Farinas M, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–87.
14. Jabbari A, et al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016;7:240–7.
15. Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16(1):S25–7.
16. Wang EH, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8):1617–26.
17. Tobin DJ, et al. Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol. 1997;109(3):329–33.
18. Leung MC, et al. Trichohyalin is a potential major autoantigen in human alopecia areata. J Proteome Res. 2010;9(10):5153–63.
19. Sundberg JP, et al. C3H/HeJ mouse model for alopecia areata. J Invest Dermatol. 1995;104(5 Suppl):16S–7S.
20. McElwee KJ, et al. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol. 1998;111(5):797–803.
21. Wang EH, et al. Transfer of alopecia areata to C3H/HeJ mice using cultured lymph node-derived cells. J Invest Dermatol. 2015;135(10):2530–2.
22. Gilhar A, Keren A, Paus R. A new humanized mouse model for alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S37–8.
23. Dai Z, et al. CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata. J Immunol. 2016;197(4):1089–99.
24. Estefan J, et al. Alopecia areata–Part II: diagnosis and pathology. Skinmed. 2015;13(2):121–6.
25. Tosti A, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol. 2008;59(1):64–7.
26. Ardigo M, et al. Reflectance confocal microscopy of the yellow dot pattern in alopecia areata. Arch Dermatol. 2011;147(1):61–4.
27. Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231–46.
28. Hordinsky MK. Current treatments for alopecia areata. J Investig Dermatol Symp Proc. 2015;17(2):44–6.
29. Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.
30. Higgins E, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–3.
31. Kennedy Crispin M, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
32. Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
33. Patel H, et al. Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism. PLoS One. 2016;11(3):e0149441.
34. Benhatchi K, et al. CTLA4 exon1 A49G polymorphism in Slovak patients with rheumatoid arthritis and Hashimoto thyroiditis-results and the review of the literature. Clin Rheumatol. 2011;30(10):1319–24.
35. Repnik K, Potocnik U. CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease patients and regulates expression of CTLA4 isoforms. DNA Cell Biol. 2010;29(10):603–10.
36. Megiorni F, et al. Cytotoxic T-lymphocyte antigen 4 (CTLA4) +49AG and CT60 gene polymorphisms in alopecia areata: a case-control association study in the Italian population. Arch Dermatol Res. 2013;305(7):665–70.
37. Nusslein HG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99.
38. Petukhova L, et al. The genetics of alopecia areata: what’s new and how will it help our patients? Dermatol Ther. 2011;24(3):326–36.
39. Ali A, Martin JMT. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol. 2010;9(1):62–4.
40. Lattouf C, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol. 2015;72(2):359–61.
41. Loi C, Starace M, Piraccini BM. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: experience of 20 patients. J Am Acad Dermatol. 2016;74(5):e99–100.
42. Moreira FT, et al. Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects. Life Sci. 2014;98(2):83–7.
43. Bolduc C, Bissonnette R. Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients. J Cutan Med Surg. 2012;16(4):257–60.
44. Hernandez MV, et al. Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol. 2009;27(5):892–3.
45. Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.
46. Freyschmidt-Paul P, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–21.
47. Freyschmidt-Paul P, et al. The functional relevance of the type 1 cytokines IFN-gamma and IL-2 in alopecia areata of C3H/HeJ mice. J Investig Dermatol Symp Proc. 2005;10(3):282–3.
48. Pham MN, von Herrath MG, Vela JL. Antigen-specific regulatory T cells and low dose of IL-2 in treatment of type 1 diabetes. Front Immunol. 2015;6:651.
49. Castela E, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748–51.
50. Guttman-Yassky E, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301–4.